While these criticisms may or may not be justified, it is probably true to say that the New York City diabetes registry, though highly innovative, is at best an interim solution. Rather than relying on laboratory reporting of a single biomarker, an ideal chronic-disease surveillance system would extract all necessary data directly from the patient record.
但不管这些批评是否中肯，我们大体可以确定的是纽约市糖尿病登记制度虽然极富创新性，却只是一个最佳的过渡方案。除了依赖实验室对某一单一生物标记的报告之外，一个直接从病人病历中提取所需数据的慢性病监测系统才是最理想的。